HDD Technology: Hyaluronan Drug Delivery

Holy Stone Healthcare focuses on biopolymers to develop novel drug delivery technologies. Our "Biopolymer drug delivery platform" exploits the biological safety, compatibility, degradability and other characteristics of natural polysaccharides. We have made full use of non-toxic, non-immunogenic, non-inflammatory, mucoadhesive, tissue penetration, and other characteristics of hyaluronic acid to develop a number of medical devices. The company has also successfully developed “Hyaluronan Drug Delivery (HDD)” technology. Since hyaluronic acid is one of the main components of extracellular matrix (ECM) serving as the ligand of receptor glycoprotein CD44 (cluster of differentiation 44) and RHAMM (receptor for hyaluronan mediated motility), we utilize hyaluronic acid as a targeting drug carrier for new drug development. Based on the Hyaluronan Drug Delivery technology, Holy Stone Healthcare has developed “Multi-layer coating pellet technology (MLCP)”, “Trans-mucosal Drug Delivery technology (TMDD)”, and “Hyaluronic acid conjugated drugs (HACD)”.